AR and cancer: In triple-negative FMCs also, AR overexpression was associated with longer disease-free interval (HR = 0.49, 95% CI: 0.28–0.85; p = 0.037) and cancer-specific survival (HR = 0.53, 95% CI: 0.32–0.89; p = 0.046).